Literature DB >> 2111744

Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.

C Bode1, M S Runge, S Schönermark, T Eberle, J B Newell, W Kübler, E Haber.   

Abstract

Single-chain urokinase plasminogen activator (scu-PA) that had been modified with N-succinimidyl-3-(2-pyridyldithio)propionate was covalently linked by disulfide bonds to the Fab' of a monoclonal antibody specific for the beta-chain of fibrin (antibody 59D8). scu-PA-59D8 Fab' conjugate was separated from free scu-PA and two-chain urokinase coupled to 59D8 Fab' by two-step affinity chromatography. First, the reaction mixture was chromatographed on a column containing Sepharose linked to the peptide that had been used as immunogen for antibody 59D8; scu-PA-59D8 Fab' conjugate and unconjugated 59D8 Fab' were retained but not unconjugated scu-PA. Then, the eluate from the peptide-Sepharose column was chromatographed on a column containing Sepharose linked to benzamidine, which acts as a ligand for two-chain urokinase. The molecular weight of the scu-PA-59D8 Fab' conjugate was approximately 100 kDa when electrophoresed on a nonreducing sodium dodecylsulfate-polyacrylamide gel. Enzymatic assay after purification revealed that more than 97% of the scu-PA present in the conjugate retained the single-chain form. The Fab' portion of the conjugate functioned in a manner indistinguishable from that of native antibody 59D8. In an in vitro assay for lysis of fibrin monomer, the fibrinolytic potency of scu-PA-59D8 Fab' was 33-fold more than that of tissue plasminogen activator (p less than 0.001), 230-fold more than that of unconjugated scu-PA (p less than 0.0001), and 420-fold more than that of urokinase (p less than 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2111744     DOI: 10.1161/01.cir.81.6.1974

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.

Authors:  M S Runge; T Quertermous; P J Zavodny; T W Love; C Bode; M Freitag; S Y Shaw; P L Huang; C C Chou; D Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 2.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

Review 3.  Vascular targeting of antithrombotic agents.

Authors:  Ronald Carnemolla; Vladimir R Muzykantov
Journal:  IUBMB Life       Date:  2011-07-15       Impact factor: 3.885

Review 4.  Cardiovascular therapies in the 1990s. An overview.

Authors:  R C Becker; J M Gore
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 5.  Thrombolytics: drug interactions of clinical significance.

Authors:  S Harder; U Klinkhardt
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

Review 6.  Thrombolytic therapy in acute myocardial infarction--selected recent developments.

Authors:  C Bode; T K Nordt; M S Runge
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

7.  Staphylokinase as a plasminogen activator component in recombinant fusion proteins.

Authors:  S J Szarka; E G Sihota; H R Habibi; S Wong
Journal:  Appl Environ Microbiol       Date:  1999-02       Impact factor: 4.792

8.  A Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-Insoluble Fibrin Antibody and Mutated Urokinase.

Authors:  Shingo Hanaoka; Shinji Saijou; Yasuhiro Matsumura
Journal:  Thromb Haemost       Date:  2021-06-15       Impact factor: 6.681

9.  Construction and expression of D-dimer and GPIIb/IIIa single-chain bispecific antibody.

Authors:  Zhaokui Dan; Zui Tan; Hongli Xia; Gan Wu
Journal:  Exp Ther Med       Date:  2013-05-30       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.